Self-report of Current and Prior Antiretroviral Drug Use in Comparison to the Medical Record Among HIV-infected Patients Receiving Primary HIV Care

Overview

Journal Pharmacoepidemiol Drug Saf

Publisher Wiley

Specialties Pharmacology
Public Health

Date 2011 Feb 5

PMID 21294218

Citations 7

Authors

Emily Suzanne Brouwer

Sonia Napravnik

Sarah G Smiley

Amanda H Corbett

Joseph J Eron Jr

Affiliations

Soon will be listed here.

Abstract

Objective: Patient antiretroviral (ARV) therapy knowledge is essential for regimen adherence, successful therapeutic response, and minimization of resistance evolution. Moreover, a complete and accurate patient ARV history is needed to construct efficacious and tolerable future regimens. In this study we assessed the ability of HIV-infected patients receiving care in a university infectious diseases clinic to accurately recall current and past ARVs.

Methods: A convenience sample (n = 205) of UNC HIV Clinical Cohort participants (n = 1840) completed a comprehensive in-person interview. Patients were asked about current and ever ARV use and were provided proprietary and generic ARV names and photographs. Self-reported sensitivity for current and ever ARV use (proportion that correctly identified all recorded ARVs), was calculated using the medical record as the gold standard.

Results: One hundred and eighty-five patients had received ARVs at some point after enrollment in the cohort study (ever users). For current ARV use (n = 138), self-reported sensitivity was 63% (95% CI: 54-71). For ever use (n = 185), sensitivity was 18% (95% CI: 13-24).

Conclusion: Self-reported cumulative ARV use is not accurate. Since HIV-infected patients are prescribed a number of medications over their treatment course, it is necessary to develop new medication reconciliation techniques that are not dependent on patient memory or knowledge in order to improve patient outcomes.

Citing Articles

Higher Clinician-Patient Communication Is Associated With Greater Satisfaction With HIV Care.

Wachira J, Mwangi A, Chemutai D, Nyambura M, Genberg B, Wilson I J Int Assoc Provid AIDS Care. 2021; 20:23259582211054935.

PMID: 34787014 PMC: 8606924. DOI: 10.1177/23259582211054935.

A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.

Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A J Med Virol. 2015; 87(10):1662-7.

PMID: 25940687 PMC: 5054847. DOI: 10.1002/jmv.24220.

HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States.

Dennis A, Wheeler J, Valera E, Hightow-Weidman L, Napravnik S, Swygard H AIDS Care. 2013; 25(10):1298-307.

PMID: 23384328 PMC: 4125118. DOI: 10.1080/09540121.2013.764964.

The state of disparities in opportunistic infection prophylaxis for blacks with HIV/AIDS.

Oramasionwu C, Koeller J, Lawson K, Brown C, Morse G, Frei C Med Care. 2012; 50(11):920-7.

PMID: 23047780 PMC: 3470654. DOI: 10.1097/MLR.0b013e31826c85d1.

Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users.

Doshi R, Vogenthaler N, Lewis S, Rodriguez A, Metsch L, Del Rio C AIDS Res Hum Retroviruses. 2012; 28(9):1007-14.

PMID: 22214200 PMC: 3423644. DOI: 10.1089/AID.2011.0329.

References

Valdez Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A . Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007; 370(9581):29-38. DOI: 10.1016/S0140-6736(07)61047-2. View

Wolf M, Davis T, Osborn C, Skripkauskas S, Bennett C, Makoul G . Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2006; 65(2):253-60. DOI: 10.1016/j.pec.2006.08.006. View

Jorgensen T, Johansson S, Kennerfalk A, Wallander M, Svardsudd K . Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001; 35(9):1004-9. DOI: 10.1345/aph.10351. View

Rosenberg M, Layde P, Ory H, Strauss L, Rooks J, Rubin G . Agreement between women's histories of oral contraceptive use and physician records. Int J Epidemiol. 1983; 12(1):84-7. DOI: 10.1093/ije/12.1.84. View

Klungel O, de Boer A, Paes A, Nagelkerke N, Seidell J, Bakker A . Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. Am J Hypertens. 2000; 13(1 Pt 1):88-91. DOI: 10.1016/s0895-7061(99)00101-6. View

Clotet B, Bellos N, Molina J, Cooper D, Goffard J, Lazzarin A . Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007; 369(9568):1169-78. DOI: 10.1016/S0140-6736(07)60497-8. View

Wood E, Kerr T, Hogg R, Zhang R, Tyndall M, Montaner J . Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr. 2006; 41(4):530-1. DOI: 10.1097/01.qai.0000199096.11215.79. View

Chen R, Westfall A, Mugavero M, Cloud G, Raper J, Chatham A . Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003; 37(5):714-22. DOI: 10.1086/377271. View

West S, Strom B, Freundlich B, Normand E, Koch G, Savitz D . Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol. 1994; 47(2):165-71. DOI: 10.1016/0895-4356(94)90021-3. View

10.

Halamka J, Mandl K, Tang P . Early experiences with personal health records. J Am Med Inform Assoc. 2007; 15(1):1-7. PMC: 2274878. DOI: 10.1197/jamia.M2562. View

11.

Dailey G, Kim M, Lian J . Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002; 30(1):71-9. DOI: 10.1177/147323000203000111. View

12.

Miller L, Liu H, Hays R, Golin C, Ye Z, Beck C . Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis. 2003; 36(4):514-8. DOI: 10.1086/367857. View

13.

Moore R, Keruly J, Gebo K, Lucas G . An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005; 39(2):195-8. View

14.

Gross R, Yip B, Lo Re 3rd V, Wood E, Alexander C, Harrigan P . A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006; 194(8):1108-14. DOI: 10.1086/507680. View

15.

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

16.

Liu H, Miller L, Hays R, Golin C, Wu T, Wenger N . Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006; 41(3):315-22. DOI: 10.1097/01.qai.0000197071.77482.6e. View

17.

Parruti G, Manzoli L, Toro P, DAmico G, Rotolo S, Graziani V . Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS. 2006; 20(1):48-56. DOI: 10.1089/apc.2006.20.48. View

18.

Harrigan P, Hogg R, Dong W, Yip B, Wynhoven B, Woodward J . Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191(3):339-47. DOI: 10.1086/427192. View

19.

Gama H, Correia S, Lunet N . Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf. 2009; 18(3):175-87. DOI: 10.1002/pds.1703. View

20.

Willig J, Abroms S, Westfall A, Routman J, Adusumilli S, Varshney M . Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008; 22(15):1951-60. PMC: 2828871. DOI: 10.1097/QAD.0b013e32830efd79. View